A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
242actual
Sites
50
Countries
Brazil, Colombia, Kenya +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision to terminate study based on results of parent study GBT2104-131.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-29 | actual | When the study began enrolling |
| Primary completion | 2025-11-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-07 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Vaso-occlusive Crisis
- Vaso-occlusive Pain Episode in Sickle Cell Disease
Intervention
- Drug: Inclacumab
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs).
measured Day 1 through study completion, an estimate of 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed